Contrarian Corpus

399 documents showing 181–240

TCI Fund 2021-08-31

Canadian National Railway CNI

CN, once the best-run Class I railroad, is now the worst under CEO Ruest; abandon the KCS deal and install Jim Vena to restore operational excellence.

N4 V3 C3
Starboard Value 2021-08-16

Box, Inc. BOX

Box has chronically lagged peers and entrenched itself via an unnecessary $500M KKR preferred financing; electing Starboard's minority slate restores stockholder accountability and unlocks long-term value.

N4 V2 C1
Starboard Value 2021-08-06

Box, Inc. BOX

Box is a best-of-breed cloud content platform that has missed every revenue target since IPO; a reconstituted board can fix go-to-market execution and close a massive valuation gap to peers.

N4 V3 C3
Starboard Value 2021-05-20

Box, Inc. BOX

Box's board issued $500m of KKR preferred to lock up >10% of the vote and entrench itself ahead of Starboard's proxy contest — Starboard demands the books and four new directors.

N3 V1 C1
Greenlight Capital 2021-05-12

Teck Resources TECK

Teck is the overlooked pick-axes play on the EV/green-electrification copper boom — QB2 doubles its copper mix and at forward-curve copper the stock is worth ~C$59, nearly double.

N4 V2 C2
Land & Buildings 2021-05-01

Hilton Grand Vacations HGV

HGV is overpaying 10x EBITDA for Diamond and handing Apollo effective control with no premium; standalone HGV is worth $55 — shareholders should vote AGAINST.

N4 V3 C3
Ancora 2021-02-16

Forward Air Corporation FWRD

Forward Air's acquisition-led growth strategy has decimated its core LTL margins; Ancora's nominees will restore operating discipline and unlock ~50% upside to $130-$135/share.

N4 V2 C2
Land & Buildings 2020-12-01

Multiple REIT subsectors (urban office, retail, business hotels, movie theaters)

Post-vaccine pent-up demand will mask permanent secular damage in urban office, retail, business hotels, and movie theaters — investors should sell the mirage, not buy it.

N4 V2 C2
Citron Research 2020-11-13

NIO Inc. NIO

NIO trades at 17-18x NTM EV/Sales — double Tesla's multiple — as a Made-in-China Model Y near $41K threatens the ES6/EC6; Citron closes its 2018 long at a $25 price target.

N3 V2 C1
Muddy Waters 2020-11-11

MultiPlan Corp MPLN

MultiPlan is a financially-engineered SPAC corpse losing its biggest customer UHC to UHC's own competitor Naviguard; expect 35% revenue loss and 8x+ leverage by 2022.

N4 V2 C2
Elliott Management 2020-11-11

Sampo Oyj SAMPO

Sampo core insurance has de-rated ~8x P/E vs Nordic peers since 2018

N4 V4 C4
Third Point 2020-10-07

The Walt Disney Company DIS

Disney should kill its $3bn dividend and plow every dollar into Disney+ content; subscriber LTV math and Adobe/Microsoft precedents show the re-rating dwarfs any dividend yield.

N4 V2 C2
Land & Buildings 2020-09-22

Apartment Investment and Management Company AIV

AIV's proposed taxable reverse spin-off won't close its 18% NAV discount and lets Considine duck 25 years of underperformance; demand a shareholder vote or explore a sale at $58 — 75% upside.

N3 V2 C1
Kerrisdale Capital 2020-09-01

AtriCure, Inc. ATRC

AtriCure's 7.5x revenue valuation assumes stand-alone Convergent succeeds, but electrophysiologists won't refer, and PFA plus real-time mapping will obsolete surgical ablation.

N4 V3 C2
Elliott Management 2020-07-06

Crown Castle International CCI

Crown Castle's fiber capex earns just 3% ROI versus ~20% for its tower business

N5 V4 C4
Land & Buildings 2020-05-19

D.R. Horton and Invitation Homes DHI/INVH

COVID-19 has supercharged the suburban single-family thesis; entry-level homebuilder D.R. Horton and single-family rental REIT Invitation Homes trade 20%+ below highs despite accelerating demand.

N3 V2 C2
Elliott Management 2020-05-12

Alexion Pharmaceuticals, Inc. ALXN

Alexion's stand-alone strategy has failed — serial M&A missteps and a deep valuation discount mean the Board must pursue a sale now to unlock 40-50% upside for shareholders.

N5 V3 C3
Starboard Value 2020-05-11

GCP Applied Technologies GCP

Starboard rebuts GCP: stock has lagged peers on every milestone since the 2016 spin-off, and Starboard's superior director slate can finally drive the turnaround management hasn't delivered.

N4 V3 C3
Land & Buildings 2020-05-06

Empire State Realty Trust ESRT

Empire State Realty Trust is uniquely exposed to NYC's 'existential hurricane' — COVID, WFH, SALT cap, and WeWork's collapse crush demand while observation-deck revenue vanishes, driving shares substantially lower.

N3 V2 C2
Starboard Value 2020-04-30

GCP Applied Technologies GCP

Four years post-spinoff, GCP has lagged peers on growth, margins, and stock price under an insular, interconnected Board; replace nine directors and unlock ~600 bps of EBIT margin expansion.

N4 V3 C3
Hindenburg Research 2020-04-20

New Pacific Metals NUAG

Bolivia-focused silver developer New Pacific trades 17x peers on concessions likely acquired illegally under a now-ousted regime; Hindenburg targets C$0.37, 90%+ downside.

N5 V4 C4
Pershing Square 2020-02-05

Pershing Square Holdings (fund) — portfolio includes Agilent, Berkshire Hathaway, Chipotle, Hilton, Restaurant Brands, Lowe's, Howard Hughes, Fannie Mae/Freddie Mac PSH

PSH delivered 58.1% NAV return in 2019, beating S&P by 2,660bps — return to roots is working

N3 V4 C3
Starboard Value 2020-02-04

eBay Inc. EBAY

eBay is deeply undervalued; separating Classifieds at peer-level ~22x EBITDA multiples and enforcing a more aggressive Marketplace cost and revenue plan would unlock substantial upside versus today's 8.1x multiple.

N4 V2 C2
Muddy Waters 2019-12-17

NMC Health plc NMC.LN

NMC Health's UAE hospital empire is built on inflated capex, overstated cash, hidden reverse factoring and related-party self-dealing — Muddy Waters is short and sees deep, possibly fraudulent rot.

N5 V1 C1
Citron Research 2019-12-10

Peloton Interactive PTON

Peloton trades at 2,286% above peers on EV per subscriber; once a cannibalizing app, undifferentiated hardware, and a March lockup wave hit, the stock collapses to $5.

N4 V2 C2
Trian Partners 2019-11-14

Ferguson plc FERG

Ferguson is a US specialty distributor trapped in a UK listing; demerging Wolseley and relisting in the US closes a 10.4x-vs-17.2x EBITDA peer gap.

N4 V3 C3
Muddy Waters 2019-11-07

PeptiDream, Inc. 4587 JP

PeptiDream's 19 pharma 'partnerships' are largely dormant and 13 years of R&D have produced zero Phase 2 drugs — analyst 2027 revenue forecasts will miss by over 60%.

N4 V2 C2
Elliott Management 2019-09-24

Marathon Petroleum Corporation MPC

Separating Marathon into three independent businesses unlocks $22-$40bn of value (60%+ upside)

N5 V4 C4
Kerrisdale Capital 2019-07-01

CareDx, Inc. CDNA

CareDx is a $1.7bn story built on AllSure, a cfDNA kidney-rejection test that misses 40% of rejections and faces 70% annual patient attrition, competition and Medicare reset — ~70% downside.

N4 V2 C2
Starboard Value 2019-06-20

AECOM ACM

AECOM is a collection of under-integrated franchises; a Jacobs-style operational overhaul plus outright sales of MS and CS can close a 5.3x multiple discount to peers.

N4 V3 C3
Third Point 2019-06-13

Sony Corporation 6758.T

Sony trades at a ~50% conglomerate discount; spinning Semiconductors into 'Sony Technologies', divesting listed stakes, and refocusing on entertainment unlocks ~2x SOTP upside.

N5 V4 C4
Citron Research 2019-06-01

FleetCor Technologies FLT

FleetCor's Clean Advantage carbon-offset program is a $100M+ green fraud — 97% of fees stay with FLT, demanding CEO Clarke's resignation and implying ~57% downside.

N4 V3 C3
Starboard Value 2019-03-18

Bristol-Myers Squibb BMY

BMY is overpaying ~$30B for Celgene's risky pipeline, betting on 10 blockbusters in 8 years vs 3 in 15; shareholders should vote against and unlock 900bps of standalone margin upside.

N5 V3 C3
Starboard Value 2019-03-01

Bristol-Myers Squibb BMY

BMY's $91B Celgene deal bets the company on a REVLIMID patent cliff and pipeline requiring 10 blockbusters in 8 years — shareholders should vote no and pursue a standalone Amgen-style transformation.

N5 V3 C3
Starboard Value 2019-02-28

Bristol-Myers Squibb Company BMY

Bristol-Myers' $91bn Celgene acquisition buys pharma's largest patent cliff; Starboard urges shareholders to vote it down and replace directors to pursue a standalone plan or sale.

N4 V3 C3
Starboard Value 2019-02-28

Bristol-Myers Squibb Company BMY

Starboard urges BMY shareholders to reject the $91B Celgene acquisition — it imports a massive REVLIMID patent cliff and was rushed through without exploring standalone turnaround or a sale of Bristol-Myers.

N4 V3 C3
Starboard Value 2019-02-22

Magellan Health, Inc. MGLN

Magellan destroyed $700M of value through failed acquisitions and three 2018 guidance cuts; Starboard's six-director slate will overhaul the board and run a parallel sale process at peer multiples.

N4 V2 C2
Citron Research 2019-02-15

Inogen INGN

Inogen's growth is built on a reseller network that lies to elderly customers about Medicare coverage to force cash sales — competition and oversight will collapse margins to a $46 stock.

N4 V2 C2
Pershing Square 2019-02-13

Pershing Square Holdings, Ltd. (annual portfolio update; covers CMG, ADP, QSR, LOW, SBUX, HLT, UTX, HHC, FNMA/FMCC) PSH

PSH trades at 27% discount to NAV despite 13.8% net CAGR since 2004 vs 8.4% for S&P 500

N3 V3 C2
Muddy Waters 2019-02-08

Inogen, Inc. INGN

Inogen's growth story rests on a fabricated TAM sourced from a plagiarism-riddled WinterGreen report; real market is shrinking, peak sales arrive 2019-2020, target $46 (-67%).

N5 V2 C2
Starboard Value 2019-01-07

Dollar Tree, Inc. DLTR

Dollar Tree is deeply undervalued because Family Dollar is a failed acquisition and the $1 price ceiling is a self-imposed cap; selling Family Dollar and testing multi-price points unlocks $150/share.

N4 V2 C2
Starboard Value 2018-12-10

Cars.com Inc. CARS

Starboard, a ~10% holder, warns Cars.com's board that serial guide-downs must end with credible 2019-2021 targets, a third independent director, and — absent improvement — management change or a sale.

N4 V2 C2
Carl Icahn 2018-11-15

Dell Technologies (Class V / DVMT tracking stock) DVMT

Dell's $109 buyout of the DVMT tracker is really $90 — a 42% discount engineered to transfer $11bn from public holders to Michael Dell and Silver Lake. Vote no.

N4 V3 C3
Citron Research 2018-10-23

Tesla, Inc. TSLA

After five years short, Citron reverses on Tesla: Model 3 is dominating luxury and EV segments, Munro confirms 30% margins, and worst-case math yields $599/share.

N4 V2 C2
Trian Partners 2018-10-11

PPG Industries, Inc. PPG

PPG has underperformed peers by 3,500 bps under CEO McGarry; Trian wants Chuck Bunch reinstalled, the balance sheet levered, and the portfolio split into Architectural and Industrial to unlock ~40% upside.

N4 V3 C3
Pershing Square 2018-10-09

Starbucks SBUX

Dominant global coffee brand trading at 22x forward P/E vs. 26x historical average

N4 V3 C3
Third Point 2018-10-01

Campbell Soup Company CPB

Campbell's incumbent board delivered 19% TSR vs 306% S&P over 20 years; replace the entire board with Third Point's Independent Slate to unlock $52-58/share via turnaround, breakup, or sale.

N5 V4 C4
Citron Research 2018-08-28

Wayfair W

Wayfair's unit economics are deteriorating — loss per new customer nearly doubled to $19 — while the stock defies gravity; Citron is re-shorting with a first stop at $100.

N3 V2 C2
Third Point 2018-07-01

Nestlé S.A. NESN

Nestlé has been too slow to adapt to a changing consumer industry; adopting a #NestléNOW mindset — sharper strategy, bolder portfolio divestitures including the L'Oréal stake, and a three-division split — can double EPS by 2022.

N5 V4 C4
Citron Research 2018-05-31

Snap Inc. SNAP

SNAP trades at largest-ever discount to FB/TWTR despite fastest revenue growth

N4 V3 C2
Carl Icahn 2018-05-24

SandRidge Energy SD

SandRidge trades at a ~45% discount to its own PV-10 because the post-bankruptcy 'bankruptcy board' destroys value via dilutive deals; replace it with Icahn's slate to run a real sale process.

N4 V3 C3
Land & Buildings 2018-05-10

Taubman Centers, Inc. TCO

Taubman's persistent peer underperformance stems from a family-entrenched board and dual-class structure; electing Litt and collapsing Series B shares unlocks value common shareholders have been denied.

N4 V3 C3
Elliott Management 2018-04-23

Hyundai Motor Group (Hyundai Mobis, Hyundai Motor Company, Kia Motors) 012330.KS / 005380.KS / 000270.KS

Mobis, HMC and Kia trade at 57%, 26% and 73% EV/EBITDA discounts to global peers — peers re-rate if structure is fixed

N5 V4 C4
Carl Icahn 2018-04-17

Xerox Corporation XRX

Xerox's CEO is handing 50.1% control to Fuji 'without spending a penny' for ~$28/share; vote down the deal and replace the board to unlock $54-$64 standalone.

N5 V3 C3
Elliott Management 2018-04-05

Telecom Italia SpA (TIM) TIT.MI

Vivendi controls TIM with just 24% voting stake, running it as a subsidiary while minorities suffer

N5 V4 C4
Carl Icahn 2018-04-02

Commvault Systems, Inc. CVLT

Commvault is a product-great but company-broken data management software leader; Elliott (10.3%) demands an operational review, four new directors, and a capital-return program to close a deep valuation discount.

N4 V2 C2
Elliott Management 2018-04-02

Commvault Systems, Inc. CVLT

Commvault, a product-respected software leader, trades at half the peer multiple because of 1,200bps of margin collapse and 20-year stale governance; a board refresh, operational review and capital return will close the gap.

N4 V2 C3
Starboard Value 2018-02-13

Monotype Imaging Holdings Inc. TYPE

Monotype's three-year acquisition spree (Olapic, Swyft) destroyed $500M+ of value and halved EBITDA margins; Starboard demands four new directors to refocus on the core font franchise.

N4 V3 C3
Starboard Value 2018-02-12

Newell Brands Inc. NWL

Starboard, backed by Jarden's founders, seeks to replace Newell's board after CEO Michael Polk destroyed $11bn of value following the 2016 Jarden merger.

N4 V2 C2
Starboard Value 2018-02-05

Mellanox Technologies, Ltd. MLNX

Mellanox insiders have sold $130M of stock across 373 trades vs. one purchase since IPO — evidence the Board lacks confidence in its own plan and must be reconstituted.

N4 V3 C3